Biovest Names Dr. Eduardo Sotomayor, Chair of Dept of Malignant Hematology at Moffitt Cancer Center, to its Scientific Adviso...
May 29 2012 - 12:30PM
Business Wire
Biovest International, Inc. (OTCQB: BVTI), a majority-owned
subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI),
today announced that Biovest has named Eduardo M. Sotomayor, M.D.
to its Scientific Advisory Board (SAB). The Biovest SAB represents
a group of preeminent physicians and doctors from the fields of
cancer immunotherapy, immunology, bioinformatics, regulatory
affairs and cell culture bio-manufacturing.
Dr. Sotomayor is a recognized visionary in the field of lymphoma
research and treatment at the H. Lee Moffitt Cancer Center &
Research Institute in Tampa, Florida, currently serving as Chair of
the Department of Malignant Hematology and holding the Susan and
John Sykes Endowed Chair for Hematological Malignancies. Dr.
Sotomayor has received multiple awards including the Lymphoma
Research Foundation (LRF) Fellowship Award and the LRF Junior
Faculty Award, as well as continued Research Project Grant (R01)
funding during the past 12-years from the National Institutes of
Health (NIH) to support his basic/translational work in the field
of immunobiology and immunotherapy of B-cell lymphomas. He is also
a member of the LRF Mantle Cell Lymphoma Consortium and serves on
the Advisory Board of several academic institutions.
Samuel S. Duffey, Biovest’s President & CEO, stated, “"We
were highly pleased and honored to have Dr. Sotomayor actively
participate in our recent advisory meetings in the EU to discuss
BiovaxID with the European national regulatory health authorities.
Throughout our regulatory process, Dr. Sotomayor has provided
Biovest with an authoritative and expert clinical viewpoint on the
use of cancer vaccine immunotherapy in the treatment of lymphoma.
We anticipate that his pioneering efforts in the field will
translate into highly productive future projects in support of our
growing relationship with the Moffitt Comprehensive Cancer
Center."
About Biovest International,
Inc.
Biovest International, Inc. is an emerging leader in the field
of active personalized immunotherapies. In collaboration with the
National Cancer Institute, Biovest has developed a
patient-specific, cancer vaccine, BiovaxID®, with three clinical
trials completed, including a Phase III study, demonstrating
evidence of safety and efficacy for the treatment of indolent
follicular non-Hodgkin’s lymphoma.
Headquartered in Tampa, Florida with its bio-manufacturing
facility based in Minneapolis, Minnesota, Biovest is
publicly-traded on the OTCQB™ Market with the stock-ticker symbol
“BVTI”, and is a majority-owned subsidiary of Accentia
Biopharmaceuticals, Inc. (OTCQB: “ABPI”).
For further information, please visit:
http://www.biovest.com
Forward-Looking
Statements:
Statements in this release that are not strictly historical
in nature constitute "forward-looking statements." Such
statements include, but are not limited to statements about
BiovaxID®, AutovaxID®, events occurring after dates hereof, and any
other statements relating to products, product candidates, product
development programs, the FDA or clinical study process including
the commencement, process, or completion of clinical trials or the
regulatory process. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, expectations and intentions, and other statements
identified by words such as "may," "could," "would," "should,"
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other factors that may cause the actual results of Biovest to be
materially different from historical results or from any results
expressed or implied by such forward-looking statements.
These factors include, but are not limited to, risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval for product candidates;
competition from other pharmaceutical or biotechnology companies;
and the additional risks discussed in filings with the Securities
and Exchange Commission. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Biovest undertakes no obligation to revise or update this news
release to reflect events or circumstances after the date hereof.
The product names used in this statement are for identification
purposes only. All trademarks and registered trademarks are the
property of their respective owners.